Sandrine Degryse Selected Research

Janus Kinase 3

1/2018	Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
11/2015	Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sandrine Degryse Research Topics

Disease

6	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2018 - 11/2014
4	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2018 - 11/2014
3	Neoplasms (Cancer) 03/2022 - 12/2014
2	Leukemia 01/2018 - 07/2015
1	Squamous Cell Carcinoma of Head and Neck 03/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 12/2014

Drug/Important Bio-Agent (IBA)

2	Janus Kinase 3IBA 01/2018 - 11/2015
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2018 - 11/2014
2	Phosphotransferases (Kinase)IBA 01/2018 - 07/2015
2	Janus Kinase InhibitorsIBA 11/2015 - 10/2015
2	Cytokine Receptors (Cytokine Receptor)IBA 11/2015 - 11/2014
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 03/2022
1	Tadalafil (Cialis)FDA Link 03/2022
1	NivolumabIBA 03/2022
1	Immune Checkpoint InhibitorsIBA 03/2022
1	CytokinesIBA 01/2022
1	Interleukin-23 (Interleukin 23)IBA 01/2022
1	Interleukin-12 (IL 12)IBA 01/2022
1	InterferonsIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2018
1	Messenger RNA (mRNA)IBA 12/2016
1	Small Interfering RNA (siRNA)IBA 12/2016
1	GANT 61IBA 12/2016
1	HhAntag691IBA 12/2016
1	Interleukin-7 (Interleukin 7)IBA 07/2015
1	venetoclaxIBA 12/2014

Therapy/Procedure

1	Immunotherapy 01/2022
1	Drug Therapy (Chemotherapy) 12/2014
1	Therapeutics 12/2014